stockrow
Monday 9 November 2026
Export PLX’s income statement to Excel — free account
Protalix BioTherapeutics, Inc.
PLXProtalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.
- Revenue
- +27.1%
- EPS
- +2,281.0%
- Free cash flow
- −94.1%
Quarter to June 2026, against a year earlier
2.54
0.03
+1.20%
Follow PLX
Alert me
Protalix BioTherapeutics, Inc. (PLX) P/E ratio
As of 6 November 2026, Protalix BioTherapeutics, Inc. (PLX) trades at a P/E ratio of 10.6×. Over the past ten years it has ranged from 0.0× (March 2026) to 67.3× (February 2025); the current reading is higher than 83% of that period. That is in line with the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 47.0× | 235.71% |
| FY2023 | 14.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 9.7× | (14.06%) |
| Mar 2026 | 11.3× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 30.8× | 70.80% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 67.3×
Ten-year median
0.0×
Current reading's percentile
45
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| PALI Palisade Bio, Inc. compare | 1.7× |
| PLX Protalix BioTherapeutics, Inc. | 10.6× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)